Topotecan-Vincristine-Doxorubicin in Stage 4 HR NBL Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study

Full title: Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.

Amoroso L, Erminio G, Makin G, Pearson ADJ, Brock P, Valteau-Couanet D, Castel V, Pasquet M, Laureys G, Thomas C, Luksch R, Ladenstein R, Haupt R, Garaventa A; SIOPEN Group.

Cancer Res Treat. 2018 Jan;50(1):148-155. doi: 10.4143/crt.2016.511. Epub 2017 Mar 21. PMID: 28324923; PMCID: PMC5784636.

Previous
Previous

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

Next
Next

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO